[1] |
BAO Lei, GENG Zihan, LI Shuran, JI Zuen, ZHAO Ronghua, SUN Jing, GUO Shanshan, CUI Xiaolan.
The critical role of TRP channels in the progression of viral pneumonia
[J]. Chinese Journal of Pharmacovigilance, 2024, 21(2): 137-140.
|
[2] |
CHEN Yuyan, ZHANG Mingxia, ZHANG Tao, ZHANG Jin.
One case of interstitial pneumonia caused by serplulimab injection
[J]. Chinese Journal of Pharmacovigilance, 2024, 21(2): 213-215.
|
[3] |
CAO Shan, PANG Bo, XU Yingli, ZHANG Jingsheng, CHEN Mengping, ZHANG Yu, WANG Yaxin, BAO Lei, GENG Zihan, GUO Shanshan, ZHAO Ronghua, CUI Xiaolan.
Effects of Shufeng Jiedu capsules prophylactic administration on TLR4-mediated inflammatory injury in lung tissue in a mouse model of inffuenza virus infeciton
[J]. Chinese Journal of Pharmacovigilance, 2024, 21(1): 45-50.
|
[4] |
ZHANG Jingsheng, GAO Shuangrong, PANG Bo, LIU Lina, XU Yingli, CAO Shan, CHEN Mengping, ZHANG Yu, ZHAO Ronghua, CUI Xiaolan.
The mechanism of Sanhan Huashi Granules on pneumonia induced by human coronavirus 229E and OC43 in mice
[J]. Chinese Journal of Pharmacovigilance, 2024, 21(1): 51-54.
|
[5] |
ZHANG Li, WANG Yujia, ZHANG Lingling, CHEN Jiaxin, LIN Minhua, LIN Xiaohui, NIE Xuekun.
Surveillance data on adverse reactions associated with real-world immune checkpoint inhibitors
[J]. Chinese Journal of Pharmacovigilance, 2023, 20(9): 1035-1038.
|
[6] |
BAO Lei, GENG Zihan, GUO Shanshan, YAO Rongmei, SUN Jing, CUI Xiaolan.
Effect of Reyanning Heji on animal models of respiratory infectious inflammation
[J]. Chinese Journal of Pharmacovigilance, 2023, 20(3): 241-247.
|
[7] |
ZHAO Ronghua, SUN Jing, BAO Lei, GENG Zihan, Li Guiping, WANG Daohan, LI Shuran, ZHANG Jingsheng, PANG Bo, XU Yingli, ZHOU Lirun, BAO Yanyan, CHEN Mengping, GUO Shanshan, CUI Xiaolan.
Effect of Jinzhen oral liquid on the model of human coronavirus pneumonia and fever epidemic immature adult mice
[J]. Chinese Journal of Pharmacovigilance, 2023, 20(3): 248-252.
|
[8] |
ZHANG Yuan, HE Mei.
Pharmaceutical care for a case of Parkinson's syndrome caused by trimetazidine hydrochloride tablets in an elderly patient with renal insufficiency
[J]. Chinese Journal of Pharmacovigilance, 2023, 20(3): 343-345.
|
[9] |
WANG Yu, HUANG Jingyi, HOU Lixin, LI Shuang, CUI Yongkang, HUANG Lanwei.
Humoral immune characteristics of peripheral blood of CAP patients with antibiotic-associated DILI
[J]. Chinese Journal of Pharmacovigilance, 2023, 20(2): 132-135.
|
[10] |
JIA Zhaoguang, XU Wenshuai, JI Li’na, WANG Linlin, ZHAO Li’na, ZHAO Jingquan, MU Xiangdong.
Diagnosis and treatment of mycoplasma pneumoniae pneumonia in children and rational administration of related drugs
[J]. Chinese Journal of Pharmacovigilance, 2023, 20(12): 1391-1395.
|
[11] |
DENG Yurong, SUN Jianhui, HAO Liyu, SHAN Zhongchao, YU Zeyue, LI Jianliang, HUO Hairu, LI Qijing, ZHANG Hongmeng, LI Hongmei.
Therapeutic effect and mechanism of Bairui granules against influenza virus-induced viral pneumonia in mice
[J]. Chinese Journal of Pharmacovigilance, 2023, 20(11): 1249-1255.
|
[12] |
PANG Bo, ZHANG Jingsheng, GUO Shanshan, SUN Jing, BAO Lei, XU Yingli, CAO Shan, CHEN Mengping, WANG Yaxin, ZHAO Ronghua, CUI Xiaolan.
Establishment and evaluation of a mouse model combining disease with syndrome of HCoV-229E pneumonia with lung-attacking damp-heat syndrome
[J]. Chinese Journal of Pharmacovigilance, 2023, 20(1): 40-45.
|
[13] |
SUN Jing, ZHAO Ronghua, BAO Lei, GUO Shanshan, GENG Zihan, LI Shuran, XU Yingli, CUI Xiaolan.
Effects of Shufeng Jiedu capsules combined with levofloxacin in the treatment of mouse pneumonia infected by multidrug-resistant Pseudomonas aeruginosa
[J]. Chinese Journal of Pharmacovigilance, 2023, 20(1): 52-56.
|
[14] |
XU Yingli, PANG Bo, CAO Shan, CHEN Mengping, SUN Jing, ZHAO Ronghua, ZHANG Jingsheng, ZHOU Lirun, WANG Yaxin, CUI Xiaolan.
Research progress in traditional Chinese medicines against multidrug-resistant Pseudomonas aeruginosa pneumonia
[J]. Chinese Journal of Pharmacovigilance, 2023, 20(1): 57-60.
|
[15] |
LIU Yantao, ZHANG Lingli, LIN Yunzhu, CHEN Li, WANG Li.
Mining and research of adverse reaction signals of pneumonia vaccines based on US Vaccine Adverse Event Reporting System
[J]. Chinese Journal of Pharmacovigilance, 2023, 20(1): 96-100.
|